Sofinnova Partners Raises $750M to Back Biotech Startups

Team S · 2025-11-20T10:24:01.000Z

Sofinnova Partners, a leading European venture capital firm, has raised €650 million ($750 million) for a new fund dedicated to life sciences. Most of the fund will support biotechnology startups developing new drugs, while 20-30% will go toward medical device makers, according to partner Maina Bhaman. The firm has already invested in five companies from this fund, including radiopharmaceuticals startup Actithera and inflammatory disease specialist Elevara Medicines. This latest fundraising comes during a rebound in life sciences investment, with global biotech funds raising $6.1 billion between July and September 2025 after a slow start earlier in the year. Sofinnova, founded over 55 years ago and managing over €4 billion in assets, focuses on being the first investor in young life sciences companies and also supports spinouts from large pharmaceutical firms, particularly those built around a single asset. Despite the influx of capital, early-stage companies have faced difficulties securing funding due to heightened investor caution and regulatory uncertainty. Challenges include changes at the U.S. Food and Drug Administration and evolving rules around pharmaceuticals, particularly for gene therapies and rare diseases. Sofinnova has announced seven investments in 2025 in startups such as Hemab Therapeutics, GlycoEra, and T-Therapeutics, and earlier launched its Biovelocita II fund, backed by Amgen, Bristol Myers Squibb, and Pfizer Ventures.

Member Login Get Access

Sofinnova Partners Raises $750M to Back Biotech Startups | Newnex